Hallo Nachteulen ! Was haltet ihr von "SCLN" (SciClone) ?

ist heute in USA 4 % im Plus, steigt seit Tagen, hat Widerstand bei 11 $ verlassen, werden bereits 2001 den breakeven haben.

Bitte um Kommentare !

... und würde mich sehr freuen, mal Eure Einschätzung zu diesem Wert (SciClone, s.o., WKN 886644)zu hören.

DANKE !!!

Harry P.

Ich würde ja gerne was sagen, habe aber noch nie was von SciClone gehört.
So geht es wahrscheinlich vielen hier. Deshalb die schwache Resonanz.

Grüsse,
Tyler

sie haben derzeit das folgende medikament bereits aktiv in 20 Ländern im Vertrieb, und zwar:

ZADAXIN: A safe and effective treatment for major, global life-threatening diseases
ZADAXIN is the safe, synthetic preparation of thymosin alpha 1, a naturally occurring peptide that enhances the ability of the body's immune system to fight and destroy cancerous and infected cells. ZADAXIN has been shown to be safe and effective in the treatment of multiple infectious diseases, including hepatitis B and hepatitis C, and several types of cancer.

ZADAXIN has now been approved for sale in 20 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems. ZADAXIN is presently in phase 2 clinical studies in the U.S. in combination with lamivudine for the treatment of hepatitis B. SciClone plans to initiate additional U.S. phase 2 ZADAXIN clinical programs in liver cancer and malignant melanoma. Pivotal phase 3 ZADAXIN hepatitis B studies are currently ongoing in Japan. SciClone plans to start a pivotal phase 3 ZADAXIN hepatitis C trial in the U.S., which trial will be complemented by a pivotal phase 3 hepatitis C trial in Europe to be conducted by Sigma-Tau S.p.A., SciClone's European partner. ZADAXIN has been administered to over 3,000 subjects in over 70 clinical trials without serious drug related side effects


weitere Infos unter www.sciclone.com, recht interessant sind auch die Daten, die man unter www.nasdaq.com mit dem Kürzel SCLN bekommt.

Danke aber für Deine Antwort - ist schon etwas frustrierend, wenn niemand schreibt ...

Harry P.

quote.bloomberg.com/...0AXRTlU2NpQ2xv&T=marketsquote99_news.ht

gegen Hepatitis A und C wenn ich es richtig erinnere,wobei Hepatitis erheblich stärker ansteckend ist als Aids und ebenfalls eine Viruserkrankung mit schweren Folgen,z.B. Nierenversagen und Dialyse www.siliconinvestor.com/research/chart.gsp?s=SCLN
interessanter Chart mit positivem MACD ,allerdings RSI schon wieder leicht abwärts gerichtet  Viel Glück  Ich nehme sie auf die Watchlist
Wkn 886644

wobei ich besonders interessant finde, daß dort in nicht allzu ferner Zukunft (Ende 2000 oder Q1/01) bereits Gewinne fließen sollen.

Grüße, Harry P.

... macht zwar keine Riesen-Sprünge, scheint sich aber als positiver Trend zu festigen ...

Happy trading, Harry P.

chart4.onvista.de/OnVista/....html?PERIOD=4&ID_NOTATION=14411" style="max-width:560px" >
News vom 12.09.02:
new`s

Reuters Company News
SciClone jumps on favorable Zadaxin cancer study
Thursday September 12, 11:20 am ET


NEW YORK, Sept 12 (Reuters) - Shares of SciClone Pharmaceuticals Inc. (NasdaqNM:SCLN - News) soared on Thursday after the firm said its drug Zadaxin boosted production of a protein that helps direct the body`s immune system to kill colorectal cancer cells.
ADVERTISEMENT


Shares of San Mateo, California-based SciClone were up 44 cents, or 18.6 percent, to $2.80, making it one of the top percentage gainers in morning activity on the Nasdaq.

Zadaxin, a synthetic form of a naturally occurring peptide meant to enhance the body`s immune system, is approved for sale in 29 countries, mainly to treat hepatitis B and hepatitis C. But it has not yet been approved in the United States.

SciClone said a new study showed a protein, or antigen, called TLP that appears only on the surface of colorectal cancer cells became more plentiful among cancer cells exposed to Zadaxin in the test tube.

The antigen acts as a flag, steering the body`s immune system to tumor cells to which it is attached, the company said. By increasing the percentage of tumor cells displaying the antigen, the immune system can theoretically better identify tumor cells and kill them.

"The (percentage) of cancer cells in culture with this protein on their surface normally ranges from 10 percent to 20 percent, but after treatment with Zadaxin this was increased to 90 percent" in the test tube experiment, SciClone said in a release.

A similar increase in the percentage of cancer cells displaying the antigen was seen in a study of animals with colorectal cancer that were treated with Zadaxin, the company said.

"To eradicate cancer cells, the immune system needs a specific target and Zadaxin has shown the potential to offer therapeutic benefit in this process," SciClone said.

Colorectal cancer kills over 50,000 Americans each year, making it nation`s second-biggest cause of cancer-related death.

Das Comeback hat etwas auf sich warten lassen, aber ist dann ja doch noch gekommen.
Kräftiger Ausbruch nach oben heute.

Gruss E.

sein, sieht sehr gut aus.

Gruss E.

chart.bigcharts.com/bc3/quickchart/...16&mocktick=1&rand=1949"

SciClone Reports Record ZADAXIN Sales for Fourth Quarter and Full Year 2002; Phase 3 Hepatitis B Clinical Trial in Japan Completed on Schedule  


SAN MATEO, Calif., Feb 4, 2003 (BUSINESS WIRE) -- SciClone Pharmaceuticals,
Inc. (Nasdaq: SCLN) today reported results for the fourth quarter ended December
31, 2002. Revenues from sales of ZADAXIN(R), the company's lead immune system
enhancer drug, reached a record $4,807,000, a 24% increase over the $3,888,000
reported for the fourth quarter of 2001. In addition, the company recognized
$223,000 as contract revenue from our European marketing partner, Sigma-Tau. For
the full year 2002, revenues from sales of ZADAXIN reached a record $17,101,000,
a 24% increase over the $13,831,000 reported for the full year 2001. Including
$671,000 of contract revenue in 2002, total revenue for the full year 2002
increased by 28.5% to $17,772,000 compared to the $13,831,000 reported for the
full year 2001.

Net loss for the fourth quarter 2002 was $2,617,000, or $0.07 per share,
compared to a net loss of $1,715,000, or $0.05 per share, for the fourth quarter
of 2001. Most of the difference was attributable to an increase in research and
development expenses to support ZADAXIN's U.S. phase 3 hepatitis C clinical
trials. Research and development expenses were $3,240,000 during the fourth
quarter of 2002 compared to $1,844,000 during the fourth quarter of 2001. For
the full year 2002, net loss was $10,037,000, or $0.29 per share, compared to
$6,232,000, or $0.19 per share, in 2001.

Cash and short-term investments totaled $21,151,000 at December 31, 2002,
compared to $24,506,000 at September 30, 2002 and $16,468,000 at December 31,
2001.

"ZADAXIN sales in international markets, primarily in China, are an important
source of funding for our U.S. clinical trials. In 2002, we significantly
increased cash flow from international sales of ZADAXIN by growing sales 24%,
holding marketing expenses flat, and improving accounts receivable and inventory
levels," said Richard A. Waldron, SciClone's Chief Financial Officer. "We expect
research and development expenses and cash disbursements to continue to increase
over the coming quarters as we progress with our phase 3 hepatitis C clinical
trials in the U.S."

Donald R. Sellers, SciClone's President and Chief Executive Officer, added,
"During 2002, we continued to make significant clinical progress towards
reaching our primary goal of ZADAXIN approvals in the U.S., Europe, and Japan.
We completed our phase 3 hepatitis B clinical trial in Japan on target at the
end of 2002 and expect to report data during the second quarter of 2003.
Particularly exciting was the hepatitis C clinical data presented at the annual
meeting of the American Association for the Study of Liver Disease (AALSD) that
showed ZADAXIN in combination with pegylated interferon alpha increased the
early virologic response rates up to 36% in patients who had failed prior
therapy. Moving forward into 2003, we continue to enroll and treat patients in
our phase 3 hepatitis C clinical trials in the U.S. and are looking forward to
another year of progress in the clinic, in research, and in our business model."

Recent developments at SciClone include: -- Sigma-Tau and its affiliates
increased their aggregate ownership to just under 10% of SciClone's common stock
outstanding through a $1.8 million investment in January 2003. Two Sigma-Tau
affiliates purchased a total of approximately 505,000 unregistered shares of
common stock at $3.5648 per share directly from SciClone. Sigma-Tau is
SciClone's marketing and development partner for ZADAXIN in the European Union
and will have access to the data from SciClone's phase 3 hepatitis C clinical
trials in the U.S. for European regulatory filing purposes. Sigma-Tau also is
funding and conducting in Europe a 300 patient phase 2 clinical trial using
ZADAXIN in combination with the standard chemotherapy for the treatment of
malignant melanoma. -- Positive data from a ZADAXIN melanoma animal study were
presented at the American Society of Clinical Oncologists (ASCO) meeting in
November 2002. This new study demonstrated that ZADAXIN treatment following
standard chemotherapy for melanoma significantly increases survival. In the
study, 60% of the group treated with ZADAXIN via continuous infusion for four
days after receiving chemotherapy survived to the 60 day endpoint. By
comparison, none of the mice receiving only chemotherapy survived after 42 days.

SciClone management will host a live audio webcast and conference call at 1:00
pm EST (10:00 am PST) today, Tuesday, February 4, 2003. The conference call will
include forward looking statements. Please log-on at www.sciclone.com or
www.vcall.com or call 800-374-0561 (U.S./Canada) or 706-634-6375 (international)
and refer to SciClone when your call is answered by the operator.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company primarily focused on the
development of Immune System Enhancers (ISEs). Its lead product ZADAXIN is in
two phase 3 hepatitis C clinical trials in the U.S., a phase 3 hepatitis B
clinical trial in Japan, a phase 2 malignant melanoma clinical trial in Europe,
and two phase 2 liver cancer clinical trials in the U.S.

ZADAXIN has been approved for sale by the ministries of health in over 30
countries and is marketed in China and selected other countries outside the U.S.
ZADAXIN has been administered to more than 10,000 patients in both clinical and
commercial use, alone and in combination with anti-viral and anti-cancer drugs,
without producing any reported ZADAXIN related significant side effects or
toxicities.

SciClone's strategic goal is to become a principal worldwide provider of Immune
System Enhancers both as monotherapies and as critical components of combination
drug therapies for infectious diseases and cancer. In addition to ZADAXIN,
SciClone's drug development opportunities include SCV-07, a potentially orally
available ISE, and products to address the protein-based disorder that causes
cystic fibrosis.

The information in this press release contains forward-looking statements
including expectations and beliefs regarding demand for ZADAXIN, expense levels,
ZADAXIN research and clinical trials, the timing and reporting of clinical trial
results and enrollment, potential regulatory approvals and the data necessary to
support such approvals. Words such as "expects," "plans," "believe," "may,"
"will," "anticipated," "intended" and variations of these words or similar
expressions are intended to identify forward-looking statements. In addition,
any statements that refer to expectations, goals, projections or other
characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking statements. These statements are not guarantees
of future performance and are subject to risks, uncertainties and assumptions
that are difficult to predict. Therefore, our actual results could differ
materially and adversely from those expressed in any forward-looking statements
as a result of various factors, including the progress or failure of clinical
trials, changes in demand for ZADAXIN, results obtained from future studies of
ZADAXIN, delays in analyzing and synthesizing data obtained from clinical
trials, future actions by the U.S. Food and Drug Administration or equivalent
regulatory authorities in Europe and in Japan, the regulatory approval process,
the statistical significance of data obtained from the clinical trials, the
speed at which patients are enrolled in trials and programs and maintenance of
the sufficiency and eligibility of the enrolled patient population, unexpected
adverse results to patients and other events that could prolong the studies or
result in unanticipated expense, as well as other risks and uncertainties
described in SciClone's filings with the Securities and Exchange Commission.

Gruss E.

Bruch des ATH aus April könnte Montag geknackt werden, mein Wunschszenario.

Gruss E.

Gruss E.

Tschüss für heute, muss zur Nachtschicht.

Gruss E.

Läuft perfekt...
Was steht bei Dir als nächstes auf dem Kaufzettel?

Hab mich nochmals mit La Jolla eingedeckt, die sind morgen auf ner Bio-Konferenz, erwarte mir da neue Details zu Requent.. da rechnen ohnehin die meisten damit, dass der Wirkstoff doch noch zugelassen wird. Was denkst Du zu La Jolla?

Grüße
Pavian

Kurs aktuell 4,44. Der Chart gefällt mir ausgezeichnet, der Downtrend wurde sicher nach oben verlassen, können schnell wieder hoch, von Zahlen unterfüttert.

Gruss E.

chart.bigcharts.com/bc3/quickchart/...18&mocktick=1&rand=1213"

ScanSoft Posts Record Fourth Quarter and Fiscal 2002 Revenue and Earnings  
       TUESDAY, FEBRUARY 25, 2003 7:17 AM
- BusinessWire

PEABODY, Mass., Feb 25, 2003 (BUSINESS WIRE) -- ScanSoft, Inc. (SSFT) , a leading supplier of digital imaging, speech and language solutions, today announced financial results for the fourth quarter and full year ended December 31, 2002.

Fourth-Quarter Results

ScanSoft reported fourth-quarter 2002 revenue of $28.4 million, a 53 percent increase over fourth-quarter 2001 revenue of $18.6 million. Net income before amortization of acquisition-related intangible assets was $6.7 million, or $0.09 per diluted share, compared with $4.7 million, or $0.08 per diluted share, in the fourth quarter of 2001. After including amortization of acquisition-related intangibles, ScanSoft reported fourth-quarter 2002 net income of $4.4 million, or $0.06 per diluted share, compared with a fourth-quarter 2001 net loss of $2.4 million, or $0.04 per share. ScanSoft's operational cash flows for the fourth quarter of 2002 were $6.1 million compared with $4.4 million in the fourth quarter of 2001.

Full Year 2002 Results

For the full year 2002, ScanSoft reported total revenue of $106.6 million, up 70 percent from revenue of $62.7 million in 2001. Net income before acquisition-related amortization and restructuring charges was $18.5 million, or $0.25 per diluted share, versus $10.6 million, or $0.19 per diluted share, for 2001. After including acquisition-related amortization and restructuring charges, ScanSoft reported net income of $6.3 million, or $0.09 per diluted share, for 2002 compared with a net loss of $16.9 million, or $0.34 per share, for 2001. ScanSoft's operational cash flows for the full year 2002 were $12.3 million.

Comments on the Fourth Quarter and Full Year

"ScanSoft closed 2002 by posting the strongest quarterly and full-year revenue, cash flow and earnings in the company's history," said Paul Ricci, chairman and CEO of ScanSoft. "During the fourth quarter, ScanSoft experienced strong performance in international markets and growth from our largest digital imaging OEM partners, which offset some weakness in domestic channel sales."

Bei SSFT gehts hoch auf 6 Dollar, wäre doch gelacht.

Fahre mit nem guten Gefühl zur Arbeit, richtig eingekauft zu haben.

Gruss E.

Des gefällt mir, 2,2 Millionen gehandelte Stücke gestern. Jetzt fast 200% seit dem Oktoberlow, na ja , gibt schlechtere Empfehlungen.

SSFT hat noch mal den Rückwärtsgang eingelegt, egal Kursziel 6 Dollar bleibt.

Gruss E.

SciClone Reports Second QuarterResults; Record ZADAXIN Sales of $16.2 Million and Net Income of $5.1Million

Business Editors/Health/Medical Writers
BIOWIRE2K

SAN MATEO, Calif.--(BUSINESS WIRE)--July 28, 2003--SciClonePharmaceuticals, Inc. (Nasdaq:SCLN) today reported net income of$5,124,000, or $0.13 per fully diluted share, for the second quarterended June 30, 2003. Revenues from sales of ZADAXIN(R), the company´slead immune system enhancer drug, reached a record $16,207,000, drivenprimarily by a significant unanticipated surge in orders related tothe SARS epidemic in China last April.